Posted by Michael Wonder on 21 Nov 2016
EMA publishes EPAR for Kisplyx
16 November 2016 - The EMA has published an EPAR for Eisai's VEGF inhibitor.
Lenvatinib mesylate (Kisplyx) was approved by the European Commission on 25 August 2016 for use in combination with everolimus for the treatment of unresectable advanced or metastatic renal cell carcinoma.
Kisplyx will be subjected to additional monitoring by the EMA.
